The market is driven by a high incidence of cancer and skin disorders, along with strong adoption of minimally invasive treatments. Advanced healthcare infrastructure, ongoing research, and the presence of key players continue to support steady market growth.
The photodynamic therapy in the United States is widely used for treating cancer and skin conditions through targeted, minimally invasive procedures. Its adoption is supported by advanced healthcare facilities, continuous clinical research, and growing awareness among patients and healthcare professionals. The U.S. photodynamic therapy market is growing due to the rising prevalence of cancer and skin disorders, increasing demand for minimally invasive treatment, and strong adoption of advanced medical technologies. Well-established healthcare infrastructure, favorable reimbursement policies, and continuous clinical research further support growth.
Additionally, increasing awareness among patients and physician, along with the preseance and physician, along with the presence of leading pharmaceutical and device companies, drives wider adoption of photodynamic therapy across clinical settings.
The global photodynamic therapy market size was estimated at USD 5.42 billion in 2025 and is predicted to increase from USD 5.9 billion in 2026 to approximately USD 12.71 billion by 2035, expanding at a CAGR of 8.9% from 2026 to 2035.
The photodynamic therapy market is expected to witness steady growth driven by technological advancements, rising demand for non-invasive treatments, and expanding use across cancer and dermatology applications, improving treatment precision and patient outcomes.
| Metric | 2024 | 2025 |
| Market Index Value | 100 | 108 |
| Growth Rate Index | 6.8% | 7.2% |
| Adoption Index | 95 | 105 |
| Demand Index | 98 | 110 |
The U.S. photodynamic therapy market shows positive numerical growth from 2024 to 2025, reflecting rising adoption, increasing demand, and steady expansion driven by advancements in minimally invasive and targeted treatment technologies.
The photosensitizer drugs segment dominated the U.S. photodynamic therapy market with a revenue share of 48% in 2025 because these agents are essential for initiating the therapeutic effect in photodynamic therapy by selectively accumulating in abnormal cells. Continuous innovation has improved their safety, efficacy, and tumour-targeting ability. Expanding approval, strong clinical adoption in oncology and dermatology, and increasing availability if advanced formulations further strengthen their leading position in achieving effective and precise treatment outcomes.
The oncology segment held a dominant share of 55% in 2025, due to the rising global burden of cancer and strong demand for targeted minimally invasive treatments. Photodynamic therapy effectively destroys tumor cells while sparing healthy tissue, making it suitable for early-stage and localized cancers. Increasing clinical adoption and expanding treatment approvals further support its leadership position.
The hospitals segment held a dominant share of 46% in 2025 due to their advanced infrastructure, availability of specialized equipment, and skilled healthcare professionals. Hospitals manage complex cancer and dermatology cases more effectively, supported by better reimbursement policies and multidisciplinary care, making them the primary settings for photodynamic therapy treatments.
The branded drugs segment led the market with 68% share in 2025 due to strong clinical efficacy, proven profiles, and widespread physician preference. Continuous innovation, regulatory approvals, and strong marketing support from key pharmaceutical companies further strengthened their dominance. These factors ensure reliable treatment outcomes, making branded the preferred choice in photodynamic therapy.
The topical segment held a dominant share of 44% in 2025 due to its ease of use, non-invasive nature, and ability to deliver localized treatment with minimal side effects. It is widely preferred in dermatology for conditions like actinic keratosis and acne, offering better compliance, cost-effectiveness, and convenience in outpatient settings.
Leading companies in the market include Biofrontera Inc., DUSA Pharmaceuticals (a Sun Pharma company), and Bausch Health. These players drive growth through advanced photosensitizing drugs, light-based devices, and dermatology-focused therapies. Continuous innovation in targeted cancer treatment, minimally invasive procedures, and improved drug formulations further strengthens their position across oncology and dermatology applications in the U.S. healthcare system.
By Product Type
By Application
By End User
By Drug Type
By Route of Administration
